Members Only Content

Subscribe to get full access

Free Preview

Pre-commercial drug developers don't have traditional fundamentals to analyze, but investors can estimate the likelihood of clinical development. 7investing Lead Advisors Simon Erickson checks in with Maxx Chatsko on his new quest to build accurate, risk-adjusted net present value (rNPV) models for drug developers.

related news & insights

  • May 16, 2025||46.1 min||||

    What’s Next for Digital Advertising? 7investing Interviews PubMatic CEO Rajeev Goel

    PubMatic just reported first quarter 2025 results. Aside from the headwinds of a DSP partner changing its bidding process, the [...]

  • May 14, 2025||2.6 min||||

    7investing Exclusive: A Deep Dive Into Rocket Lab

    The space economy is hitting an inflection point. And that will be good news for its earliest investors. Eastern European [...]

  • May 8, 2025||0 min||||

    DraftKings Deep Dive: May 2025

    DraftKings Recommendation Report